Ann: Novogen submits IND Application to the FDA for Cantrixil-NRT.AX, page-63

First 63 Last

Share
Profile

Follow
Merchant2000

21,911 Posts.

899

12/08/16

08:25

Post #: 18500725
Share

Originally posted by novogenbuyer ↑

I feel extremely lucky to have added this morning on NASDAQ. I got a great price! I can't believe how low some people will sell this for.

But, regardless of the current SP, my confidence in Novogen is slowly starting to be restored. I have to admit that with the long period without news, I was beginning to wonder what they were working on, if anything. It seems that those worries were unfounded.

Ironically, with the IND submission, no news will actually be good news now. If 30 days pass without any questions from the FDA, we'll automatically be cleared for the clinic. I would assume that with the extensive consultations that they have had with the FDA over the past year plus, if any questions arise, they would be minor.

Once we are in the clinic, I think it will be much easier to calculate a more accurate estimate of Novogen's value. I have found a number of official statistics regarding phase I clinical companies and their success rates, so once we are in the clinic, I will calculate that out. Certainly there are still a lot of unknowns here, but buying at near cash levels in a company with several chances to potentially produce new standard-of-care drugs seems like a no-brainer to me.

Expand

Agree, so many are prepared to sell cheaply - whether sellers are being cautious or totally frustrated in recent times - no one really knows

Am surprised that NVGN ( Nasdaq) is only up 9.53% today

In the past news like this would see an 30% plus increase

NRT Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

What each US election outcome would mean for Australian companies & investors

Making money: How many microcaps should be in an investor's portfolio?